Seyed Khalafi, MD
Interventional Cardiology · Fort Worth, TXNPI 1265896393
Payments from drug & device makers
Across 186 payments — averaging $100.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$5K
- Shockwave Medical, Inc$4K
- Abiomed$2K
- Atricure, Inc.$1K
- Biotronik Inc.$1K
- Getinge USA Sales, LLC$885
- plus $4K from 25 others
What the payments were for
- Travel & lodging$3,83220%
- Food & beverage$14,92480%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 43 | $5,181 |
| Shockwave Medical, Inc | 37 | $4,212 |
| Abiomed | 15 | $1,654 |
| Atricure, Inc. | 6 | $1,425 |
| Biotronik Inc. | 12 | $1,150 |
| Getinge USA Sales, LLC | 14 | $885 |
| Penumbra, Inc. | 5 | $635 |
| Stryker | 3 | $632 |
| Maquet Cardiovascular L.L.C. | 9 | $558 |
| Boston Scientific | 2 | $491 |
| Kestra Medical Technology Services, Inc. | 2 | $350 |
| Medtronic | 3 | $271 |
| Teleflex LLC | 2 | $209 |
| Baxter Healthcare | 3 | $145 |
| Integra Lifesciences Corporation | 1 | $132 |
| Artivion, Inc. | 5 | $125 |
| Cardiva Medical, Inc. | 2 | $115 |
| Siemens Medical Solutions USA, Inc. | 1 | $112 |
| AstraZeneca | 6 | $108 |
| Bolton Medical Inc | 1 | $71 |
| Inari Medical, Inc. | 1 | $59 |
| Novo Nordisk | 2 | $46 |
| Abbott | 2 | $38 |
| Pfizer | 2 | $35 |
| Boehringer Ingelheim | 1 | $28 |
| Novartis | 1 | $23 |
| Terumo Medical Corporation | 1 | $18 |
| Philips North America LLC | 1 | $17 |
| Heartflow, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$3,600
- SAPIEN 3 Ultra RESILIA$2,283
- SYNERGY ABLATION SYSTEM$1,333
- Impella$1,280
- ATRICURE CRYOICE CRYOABLATION SYSTEM (CRYO2)$930
- Orsiro Mission$662
- Edwards SAPIEN 3 Transcatheter Heart Valve$658
- Indigo System$582
- Acrobat-I Stabilizer$521
- 1688$420
- Assure WCD$350
- HeartString III Proximal Seal$236
- SPY-PHI SYSTEM$167
- NHancer Rx$149
- Micra$147
- Acclarent Aera$132
- Inspira Air$132
- RELIEVA SPINPLUS NAV$132
- TruDi Probe$132
- Vasoview Hemopro 2$129
How this compares
$18,771 in reported general payments places this provider in the 65th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 92 | $74,876 |
| XareltoRivaroxaban | 11 | $8,907 |
| Metoprolol Succinate | 120 | $1,205 |
| ClopidogrelClopidogrel Bisulfate | 91 | $995 |
| Atorvastatin Calcium | 42 | $423 |
| Amlodipine Besylate | 54 | $363 |
| Losartan Potassium | 75 | $345 |
| Rosuvastatin Calcium | 16 | $313 |
| Lisinopril | 28 | $275 |
| Metoprolol Tartrate | 22 | $171 |
| Carvedilol | 50 | $161 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 24 | $158 |
| Furosemide | 30 | $106 |
| Spironolactone | 16 | $85 |
| Hydrochlorothiazide | 20 | $63 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $35 | $74,87692 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Fort Worth
- Elizabeth HolperFort Worth$663K
- Sukesh BurjonroppaFort Worth$233K
- Tyler BloomerFort Worth$230K
- Robert StolerDallas$8.2M
- James ChoiDallas$5.2M
- Srinivasa PotluriPlano$5.1M
- Neal KleimanHouston$4.8M
- Juan GranadaHouston$4.3M
- Ira LieberKingwood$3.3M
- Cara Ann EastDallas$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.